Key facts
- BioRender’s last known valuation is $900.0M (Oct 2025).
- It has raised $17.2M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Y Combinator, Sequoia Capital, Liquid 2 Ventures, FundersClub, Fifty Years — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for BioRender
- ·The full record, as it builds
Funding rounds
No funding rounds for BioRender are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioRender
Developer of a science illustration software designed to empower the world to learn and communicate science through visuals. The company's platform enables scientists to create their compositions without drawing, export their custom images in their preferred format, and showcase their research, allowing scientist to quickly and easily communicate their findings.
- Sector
- Information Technology
- HQ
- Toronto, Canada
- Founded
- 2017
- Employees
- 238
- Website
- biorender.com/
- Ownership
- Privately Held (backing)
BioRender doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioRender shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioRender in its N-PORT filings yet. We sweep new filings monthly.